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Abstract 
Background: The metabolic effects of omega-6 polyunsaturated fatty acids (PUFAs) remain contentious, 
and little evidence is available regarding their potential role in primary prevention of type 2 diabetes. We 
aimed to assess the associations of linoleic acid and arachidonic acid biomarkers with incident type 2 
diabetes. Methods: We did a pooled analysis of new, harmonised, individual-level analyses for the 
biomarkers linoleic acid and its metabolite arachidonic acid and incident type 2 diabetes. We analysed 
data from 20 prospective cohort studies from ten countries (Iceland, the Netherlands, the USA, Taiwan, 
the UK, Germany, Finland, Australia, Sweden, and France), with biomarkers sampled between 1970 and 
2010. Participants included in the analyses were aged 18 years or older and had data available for linoleic 
acid and arachidonic acid biomarkers at baseline. We excluded participants with type 2 diabetes at 
baseline. The main outcome was the association between omega-6 PUFA biomarkers and incident type 2 
diabetes. We assessed the relative risk of type 2 diabetes prospectively for each cohort and lipid 
compartment separately using a prespecified analytic plan for exposures, covariates, effect modifiers, 
and analysis, and the findings were then pooled using inverse-variance weighted meta-analysis. Findings: 
Participants were 39 740 adults, aged (range of cohort means) 49-76 years with a BMI (range of cohort 
means) of 23·3-28·4 kg/m(2), who did not have type 2 diabetes at baseline. During a follow-up of 366 073 
person-years, we identified 4347 cases of incident type 2 diabetes. In multivariable-adjusted pooled 
analyses, higher proportions of linoleic acid biomarkers as percentages of total fatty acid were 
associated with a lower risk of type 2 diabetes overall (risk ratio [RR] per interquintile range 0·65, 95% CI 
0·60-0·72, p 
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Summary
Background The metabolic effects of omega-6 polyunsaturated fatty acids (PUFAs) remain contentious, and little 
evidence is available regarding their potential role in primary prevention of type 2 diabetes. We aimed to assess the 
associations of linoleic acid and arachidonic acid biomarkers with incident type 2 diabetes.
Methods We did a pooled analysis of new, harmonised, individual-level analyses for the biomarkers linoleic acid and 
its metabolite arachidonic acid and incident type 2 diabetes. We analysed data from 20 prospective cohort studies 
from ten countries (Iceland, the Netherlands, the USA, Taiwan, the UK, Germany, Finland, Australia, Sweden, and 
France), with biomarkers sampled between 1970 and 2010. Participants included in the analyses were aged 18 years 
or older and had data available for linoleic acid and arachidonic acid biomarkers at baseline. We excluded participants 
with type 2 diabetes at baseline. The main outcome was the association between omega-6 PUFA biomarkers and 
incident type 2 diabetes. We assessed the relative risk of type 2 diabetes prospectively for each cohort and lipid 
compartment separately using a prespecified analytic plan for exposures, covariates, effect modifiers, and analysis, 
and the findings were then pooled using inverse-variance weighted meta-analysis.
Findings Participants were 39 740 adults, aged (range of cohort means) 49–76 years with a BMI (range of cohort 
means) of 23∙3–28∙4 kg/m², who did not have type 2 diabetes at baseline. During a follow-up of 366 073 person-years, 
we identified 4347 cases of incident type 2 diabetes. In multivariable-adjusted pooled analyses, higher proportions 
of linoleic acid biomarkers as percentages of total fatty acid were associated with a lower risk of type 2 diabetes 
overall (risk ratio [RR] per interquintile range 0∙65, 95% CI 0∙60–0∙72, p<0·0001; I²=53·9%, pheterogeneity=0·002). The 
associations between linoleic acid biomarkers and type 2 diabetes were generally similar in different lipid 
compartments, including phospholipids, plasma, cholesterol esters, and adipose tissue. Levels of arachidonic acid 
biomarker were not significantly associated with type 2 diabetes risk overall (RR per interquintile range 0∙96, 
95% CI 0∙88–1∙05; p=0∙38; I²=63·0%, pheterogeneity<0·0001). The associations between linoleic acid and arachidonic 
acid biomarkers and the risk of type 2 diabetes were not significantly modified by any prespecified potential sources 
of heterogeneity (ie, age, BMI, sex, race, aspirin use, omega-3 PUFA levels, or variants of the FADS gene; all 
pheterogeneity≥0∙13).
Interpretation Findings suggest that linoleic acid has long-term benefits for the prevention of type 2 diabetes and 
that arachidonic acid is not harmful.
Funding Funders are shown in the appendix.
Introduction
The influence of omega-6 polyunsaturated fatty acids 
(PUFAs), in particular linoleic acid—the predominant 
omega-6 PUFA—on health remains disputed.1,2 Most 
major guidelines, including those from the American 
Heart Association and Dietary Guidelines for Ameri-
cans,3,4 recommend that 5–10% of energy is obtained 
from linoleic acid, which is primarily derived from 
vegetable oils. However, some researchers have hypo-
thesised that linoleic acid might be harmful because 
it competes with omega-3 PUFA or because its 
metabolite arachidonic acid might have harmful 
effects.5,6 In response to such concerns, French national 
guidelines7 have recommended limiting linoleic acid 
consumption to no more than 4% of energy.
Although many studies4,8 have investigated the 
cardiovascular effects of omega-6 PUFAs, less is known 
about their influence on other major outcomes, such as 
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type 2 diabetes. A meta-analysis9 of randomised controlled 
feeding trials indicated that total PUFA consumption 
(predominantly linoleic acid) improves both glycaemia 
and insulin resistance. However, whether such short-term 
benefits translate to primary prevention of type 2 diabetes 
remains unclear. Most longitudinal studies10 of linoleic 
acid and incident type 2 diabetes have relied on self-
reported dietary estimates of intake that might be affected 
by errors or bias in recall. Linoleic acid cannot be 
synthesised by human beings, and thus biomarker 
measurements of linoleic acid can provide objective 
assessments that are free of memory errors, recall bias, or 
inaccuracies of food databases.11 Biomarker measurements 
are also crucial for studying the effects of arachidonic acid, 
for which levels are tightly regulated and less correlated 
with dietary intake.12 However, only a handful of pro-
spective studies10 have evaluated associations be tween 
linoleic acid or arachidonic acid biomarkers and type 2 
diabetes, resulting in potential limitations of publication 
bias and inadequate power to assess inter actions by 
demographic, medical, or genetic characteristics. Thus, 
the potential effects of omega-6 PUFAs, including 
linoleic acid and its metabolite arachidonic acid, on type 2 
diabetes remain unresolved and are of considerable 
clinical, scientific, and public health importance. To 
address these questions, we did a pooled analysis of new, 
harmonised, individual-level data within the Fatty Acids 
and Outcomes Research Consortium.13 Our primary aim 
was to assess the associations of linoleic acid and arach-
idonic acid biomarkers with incident type 2 diabetes, with 
additional aims to assess factors that might modify 
these associations. We hypothesised that the level of 
linoleic acid biomarkers, but not arachidonic acid bio-




In this pooled analysis, we identified prospective co-
 hort studies that had assessed circulating or tissue 
biomarkers of linoleic acid and arachidonic acid, and 
incidence of type 2 diabetes. Studies were identified by 
Research in context
Evidence before this study
We searched MEDLINE from inception to Feb 10, 2016, using 
the search terms “omega-6”, “linoleic acid”, “arachidonic 
acid”, “diabetes mellitus”, “cohort studies”, “prospective 
studies”, and “nested case control studies”, for articles 
published in English, manually searched reference lists of 
previous original publications and systematic reviews, and 
contacted experts to identify prospective observational 
studies that assessed the association between linoleic acid 
(the main dietary omega-6 polyunsaturated fat) and its 
downstream metabolite, arachidonic acid, and the risk of 
incident type 2 diabetes. We identified few previous studies 
that had investigated the association between linoleic acid 
and arachidonic acid biomarkers and type 2 diabetes; most 
relied on estimated levels of consumption from self-reported 
questionnaires, for which evidence has been considered weak. 
Although biomarkers of linoleic acid and arachidonic acid 
offer objective assessment of exposure that is free of recall 
bias, only a handful of prospective studies have evaluated 
associations between linoleic acid or arachidonic acid 
biomarkers and type 2 diabetes, with potential limitations of 
publication bias, and inadequate power to evaluate 
interactions by population characteristics.
Added value of this study
We did a new, harmonised analysis of individual-level data 
from 20 prospective cohort studies to assess the association 
between levels of linoleic acid and arachidonic acid 
biomarkers and the risk of incident type 2 diabetes. Data from 
366 703 person-years of follow-up of more than 
39 000 adults without type 2 diabetes at baseline showed a 
linear inverse association between levels of the biomarker 
linoleic acid and the incidence of type 2 diabetes, with similar 
findings across different lipid compartments. Conversely, 
overall levels of the biomarker arachidonic acid were not 
significantly associated with type 2 diabetes. To the best of 
our knowledge, this is the largest and most detailed 
assessment of objective biomarkers of omega-6 
polyunsaturated fatty acids and the incidence of type 2 
diabetes. The breadth and scope of the cohorts allowed 
further assessment of heterogeneity. Despite the diversity of 
the 20 contributing cohorts, evidence did not indicate that 
the associations differed by age, BMI, sex, race, omega-3 
polyunsaturated fatty acid levels, aspirin use, or variation in 
the genes encoding fatty acid desaturase.
Implications of all the available evidence
The prevalence of type 2 diabetes is escalating rapidly around 
the world, so identification of dietary and other modifiable 
risk factors for the prevention of the disease is of clinical, 
scientific, and public health importance. Several dietary 
guidelines recommend increased linoleic acid consumption to 
improve blood cholesterol levels and reduce cardiovascular 
risk. Our analysis provides novel findings that, when 
combined with in-vitro experimental and shorter-term 
interventions for metabolic risk factors, suggest that linoleic 
acid has an additional role for prevention of type 2 diabetes in 
healthy populations. Additionally, our findings do not 
corroborate concerns about potential harmful effects of 
arachidonic acid. Consistent with these findings, a recent 
systematic review found that levels of the biomarker 
arachidonic acid were associated with lower incidence of 
coronary heart disease.
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contacting experts, manual searches of reference lists of 
previous original publications and systematic reviews, 
and online searches of MEDLINE from inception to 
Feb 10, 2016, using the search terms “omega-6”, “linoleic 
acid”, “arachidonic acid”, “diabetes mellitus”, “cohort 
studies”, “prospective studies”, and “nested case control 
studies”.
Participants included in the analysis were aged 18 years 
or older, with available data for linoleic acid and arachidonic 
acid biomarkers at baseline. Participants with type 2 dia-
betes at baseline were excluded. Each cohort receieved 
institutional review board approval from their respective 
institutions and written consent was obtained from all 
participants.
Uniform analysis protocol
A standardised analysis protocol was developed and 
provided to researchers for each participating cohort. 
To reduce heterogeneity, the analysis plan included 
harmonised specifications for population inclusion, 
exposures, covariates, effect modifiers, outcomes, and 
analysis, and specifications for methods for pooling 
results. Individual scientists analysed individual-level 
data from each cohort and provided the results using 
prespecified standardised electronic forms, which were 
sent to JHYW for pooling.
Procedures
Fatty acid levels were assessed in each study in various 
lipid compartments and expressed as the proportion of 
total fatty acids (appendix).
Incident type 2 diabetes was defined by whichever of 
the following criteria were met first: a fasting glucose 
concentration of 126 mg/dL (7·0 mmol/L) or higher, 
a glucose concentration of 200 mg/dL (11·1 mmol/L) or 
higher as measured by a 2 h post-oral glucose tolerance 
test, new use of insulin or oral hypoglycaemic medi-
cation, fasting or non-fasting HBA1c concentrations of 
6∙5% or more, or by self-reported physician diagnosis in 
some cohorts (appendix).
On the basis of biological interest and well established 
associations with type 2 diabetes risk, prespecified 
covariates were age, sex, race, site of patient recruitment if 
applicable, BMI, education, smoking, physical activity, 
alcohol intake, prevalent coronary heart disease, treatment 
for hypertension, treatment for hypercholesterolaemia, 
and biomarker omega-3 PUFA concentrations (appendix). 
Participants with missing categorical covariates were inc-
luded via missing indicator categories.
To minimise concerns about multiple testing, we pre-
specified all potential sources of heterogeneity on the 
basis of demographic, anthropometric, or biological im-
portance. Cohort-specific analyses were stratified by age, 
sex, race, BMI, long-chain omega-3 PUFA biomarker 
concentrations, aspirin use (which might promote 
formation of arachidonic acid-derived resolvers of inflam-
mation), and common genetic variations in the fatty acid 
desaturase (FADS) genes (ie, FADS1 [single nucleotide 
polymorphism rs174547]), which most strongly associates 
with omega-6 PUFA levels (appendix).14
Cohort analyses
For prospective cohorts with time-to-event data, Cox 
proportional hazards were used to obtain the hazard ratio 
(HR) and SE. For studies with a case-cohort design, 
weighted Cox models were used.15 Participants were 
followed up from time of fatty acid measurement to time 
of diagnosis of type 2 diabetes, death, or cen soring at the 
end of follow-up. For a prospective case-cohort16 and 
prospective case-control study17 without time-to-event 
data, logistic regression (weighted for case-cohort studies) 
was used to obtain the odds ratio (OR) and SE for incident 
type 2 diabetes. All analyses used robust SEs.
To reduce likelihood of reverse causation as a result of 
prevalent subclinical disease, sensitivity analyses were 
done in each cohort, excluding cases diagnosed in the 
first 2 years of follow-up. To minimise exposure mis-
classification due to changes in fatty acid levels over time, 
we also did a sensitivity analysis for each cohort, censoring 
participants after the initial 6 years of follow-up.
Data pooling and meta-analysis
We used HRs and ORs to approximate relative risks 
(RRs) and pooled the data to generate summary results 
using inverse-variance weighted meta-analysis. We also 
used random effects models in sensitivity analyses.18 
Because fatty acids were measured in different lipid 
compartments (phospholipids, plasma, cholesterol esters, 
and adipose tissue) using differing methods, linoleic 
acid and arachidonic acid were evaluated continuously 
per study-specific interquintile range (the distance 
between the midpoint of the first and fifth quintiles) to 
facilitate pooling. We pooled results separately for each 
lipid com partment and across all studies. For studies 
with multiple measures, we prioritised the overall pooled 
analysis on the basis of the biomarkers that would best 
reflect long-term intake, as specified in the following 
ordered list: adipose tissue, erythrocyte phospholipids, 
plasma phos pholipids, total plasma or serum, and 
cholesterol esters.12
We assessed potential non-linear relationships by 
pooling the HR or OR for each study-specific quintile, 
established as an indicator variable against the lowest 
quintile as the reference; and in each compartment by 
multivariate inverse-variance weighted meta-regression, 
modelling the fatty acid quintile results using restricted 
cubic splines.19,20 Because findings across compartments 
could not be pooled using restricted cubic splines, these 
analyses were considered exploratory. Heterogeneity was 
assessed using the I² statistic. Statistical significance of 
differences between prespecified subgroups was assessed 
using inverse-variance weighted meta-regression. We 
used STATA (version 13.1) with a two-sided α level of 
0·05 for all meta-analyses.
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Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, writing of the report, or the 
decision to submit for publication. The corresponding 
author had full access to all the data. All authors had final 
responsibility for the decision to submit for publication.
Results
20 (77%) of the 26 studies identified agreed to participate 
by February, 2016. Overall, we included 39 740 adults from 
20 cohorts in ten countries (USA, Iceland, the Netherlands, 
Germany, Finland, the UK, Sweden, France, Australia, and 
Taiwan) in the analyses. Participants with missing 
continuous covariates were excluded (maximum exclusion 
for an individual covariate was 3·3%). Our analyses 
included 17 prospective cohort studies, two prospective 
case-cohort studies, and one nested case-control cohort 
study. Table 1 shows the baseline characteristics of the 
studies and the participants. The ranges of the mean 
cohort ages (49–76 years) and BMI (23·3–28·4 kg/m²) 
were wide. Within cohorts, even wider age ranges and BMI 
ranges were represented (appendix). Most participants 
were of European descent, although several cohorts 
included greater than 10% of individuals of African 
(Insulin Resistance Atherosclerosis Study [IRAS; 24·5%], 
Multi-Ethnic Study of Atherosclerosis [MESA; 23·9%], 
Cardiovascular Health Study [11·1%]), Asian (Chin-Shan 
Community Cardiovascular Cohort Study [100%], 
MESA [25·6%]), or Hispanic (IRAS [33·2%], MESA [22·2%]) 
descent (appendix).
Fatty acid biomarkers were measured in phospholipids 
(n=14 cohorts), total plasma or serum (n=6), cholesterol 
esters (n=4), and adipose tissue (n=1); and in six cohorts, 
measurements were done in more than two lipid 
compartments. With the exception of the Uppsala 
Longitudinal Study of Adult Men-50 (1970–73) cohort, 
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AGES-Reykjavik Iceland 2002–06 PC 753 309 (41%) 76 (5·2) 27 (4) Plasma phospholipids 28 7·8
AOC Netherlands 2002–06 PC 2888 2282 (79%) 69 (5·6) 27 (4) Cholesterol esters 154 4·8
ARIC USA 1987–89 PC 3494 1642 (47%) 54 (5·6) 27 (4) Plasma phospholipids 304 9·0
CCCC Taiwan 1992–93 PC 616 370 (60%) 59 (9·9) 23 (3) Total plasma 128 8·1
CHS USA 1992–93 PC 3179 1240 (39%) 72 (5·2) 26 (5) Plasma phospholipids 284 18·0
EPIC-Norfolk UK 1993–97 PCC 383 203 (53%) 64 (8·1) 28 (4) Erythrocyte phospholipids, 
plasma phospholipids
199 12·1
EPIC-Potsdam Germany 1994–98 PNC 2165 823 (38%) 49 (8·9) 26 (4) Erythrocyte phospholipids 488 10·1
FHS USA 2005–08 PC 1913 823 (43%) 64 (8·3) 28 (5) Erythrocyte phospholipids 98 9·0
HPFS USA 1994 PC 1545 1545 (100%) 65 (8·6) 26 (3) Erythrocyte phospholipids, 
Total plasma
113 17·6
IRAS USA 1992–94 PC 719 316 (44%) 55 (8·5) 28 (6) Total plasma 146 5·0
KIHD Finland 1991–92 (men) 
2003 (women)
PC 3145 2327 (74%) 56 (7·1) 27 (4) Serum 595 26·8
MCCS Australia 1990–94 PNC 4046 1821 (45%) 55 (8·6) 27 (5) Plasma phospholipids 336 9·9
MESA USA 2000–02 PC 2230 1026 (46%) 61 (10·1) 28 (5) Plasma phospholipids 297 11·2




NHS USA 1990 PC 1595 0 60 (6·4) 25 (4) Erythrocyte phospholipids, 
total plasma
154 22·8
PIVUS Sweden 2001–04 PC 861 422 (49%) 70 (0·2) 27 (4) Cholesterol esters, plasma 
phospholipids
69 10·9
3C France 1999–00 PC 1220 464 (38%) 74 (4·8) 26 (4) Erythrocyte phospholipids, 
total plasma
36 13·0
ULSAM-50 Sweden 1970–73 PC 1891 1891 (100%) 50 (0·6) 25 (3) Cholesterol esters 246 42·3
ULSAM-70 Sweden 1991–95 PC 738 738 (100%) 71 (0·6) 26 (3) Adipose tissue 99 21·5
WHIMS USA 1996 PC 5799 0 70 (3·8) 28 (5) Erythrocyte phospholipids 502 14·1
Data are n, n (%), or mean (SD), unless otherwise specified. Characteristics were correct at the time of fatty acid biomarker measurement. References for all studies are shown in the appendix. AGES-Reykjavik=Age, 
Gene/Environment Susceptibility Study (Reykjavik). AOC=Alpha Omega Cohort. ARIC=Atherosclerosis Risk in Communities. CCCC=Chin-Shan Community Cardiovascular Cohort Study. CHS=Cardiovascular Health 
Study. EPIC-Norfolk=European Prospective Investigation into Cancer (Norfolk). EPIC-Potsdam=European Prospective Investigation into Cancer (Potsdam). FHS=Framingham Heart Study. HPFS=Health Professionals 
Follow-up Study. IRAS=Insulin Resistance Atherosclerosis Study. KIHD=Kuopio Ischaemic Heart Disease Risk Factor Study. MCCS=Melbourne Collaborative Cohort Study. MESA=Multi-Ethnic Study of Atherosclerosis. 
METSIM=Metabolic Syndrome in Men Study. NHS=Nurses’ Health Study. PIVUS=Prospective Investigation of the Vasculature in Uppsala Seniors. 3C=Three City Study. ULSAM-50=Uppsala Longitudinal Study of Adult 
Men-50. ULSAM-70=Uppsala Longitudinal Study of Adult Men-70. WHIMS=Women’s Health Initiative Memory Study. PC=prospective cohort. PCC=prospective nested case-control. PNC=prospective nested 
case-cohort.
Table 1: Baseline cohort characteristics from 20 studies with linoleic acid and arachidonic acid biomarker measures and follow-up data for incident type 2 diabetes
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baseline blood was sampled between 1987–89 and 
2002–06. All studies used gas chromato graphy to measure 
fatty acid biomarkers, with interassay co efficients of 
variation less than or equal to 15% (appendix). The median 
percentage of linoleic acid in total fatty acid in each cohort 
ranged from 8·3% in erythrocyte phospholipids to 54·5% 
in plasma cholesterol esters (appendix). The median 
percentage of arachidonic acid in total fatty acid ranged 
from 0·3% in adipose tissue to 17·0% in erythrocyte 
phospholipids (appendix). Spearman correlations across 
lipid com partments within the six studies that included 
more than one measure ranged from 0·38 to 0·84 for 
linoleic acid and from 0·48 to 0·92 for arachidonic acid 
(appendix).
During 366 073 person-years, 4347 participants 
developed type 2 diabetes (appendix). In pooled analyses, 
linoleic acid levels were inversely associated with incidence 
of type 2 diabetes, with a lower risk in continuous analyses 
per interquintile range (fixed-effect RR 0·65, 95% CI 
0·60–0·72, p<0·0001) and in categorical analysis 
(quintile 5 vs quintile 1; 0·57, 0·51–0·64, p<0·0001; 
table 2). Findings were similar across lipid compartments 
(figure 1; table 2), although not statistically significant in 
adipose tissue, for which only one study provided data 
(99 incident cases out of 738 participants). Heterogeneity 
in the overall pooled analysis was moderate (I²=53·9% for 
continuous analyses, 46·3% for categorical analyses; 
table 2).
Arachidonic acid biomarkers were not associated with 
incidence of type 2 diabetes overall (RR per interquintile 
range 0·96, 95% CI 0·88–1·05, p=0·38; table 1, figure 2). 
Arachidonic acid biomarker concentrations in separate 
lipid compartments were not associated with type 2 
diabetes, with the exception of total plasma, whereby an 
inverse association was identified (RR per interquintile 
range 0·73, 95% CI 0·62–0·86, p=0·0003; I²=63∙8%; 
table 1, figure 2).
Categorical analysis across quintiles showed that 
participants in each of the higher quintiles (2–5) of linoleic 
acid biomarker had significantly lower risk than 
participants within the lowest quintile (figure 3). 
Additionally, the dose–response association between 
linoleic acid biomarker and type 2 diabetes appeared 
monotonic (appendix).
Restricted cubic spline regression analysis within each 
lipid compartment found little evidence for non-linearity in 
the relationship between linoleic acid biomarkers in 
cholesterol esters or total plasma and incident type 2 dia-
betes (pnon-linearity≥0·4 each; plinearity<0·001 each; appendix). 
A potentially non-linear association was identified in 
erythrocyte phospholipids (pnon-linearity=0·005) and plasma 
phospholipids (pnon-linearity=0·03; appendix); risk for each 
association declined steeply initially then plateaued (but did 
not significantly increase) at very high levels. For 
arachidonic acid, levels of biomarker in total plasma were 
associated with lower risk (plinearity<0·001), with little 
evidence for non-linear asso ciations within any of the 
compartments (pnon-linearity≥0·47; appendix). Although overall 
arachidonic acid biomarker levels in phos pholipids were 
not associated with type 2 diabetes (table 2, figure 2), 
exploratory restricted cubic spline analyses, which assessed 
erythrocyte phospholipids (plinearity=0·001) and plasma 
phospholipids (plinearity=0·03) separately, suggested divergent 
linear associations with type 2 dia betes (appendix).
The associations of linoleic acid and arachidonic acid 
biomarkers with incident type 2 diabetes did not 
significantly vary according to any prespecified potential 
sources of heterogeneity (pheterogeneity≥0·13 each; appendix). 
In the 12 cohorts with available genetic data, genetic 





Continuous analysis‡ Quintile 5 vs quintile 1
I² (%) Relative risk fixed effect Relative risk random effect I² (%) Relative risk fixed effect Relative risk random effect
Linoleic acid
Phospholipids 14 2979 58·4% 0·69 (0·61–0·77) 0·64 (0·53–0·78) 56·3% 0·60 (0·52–0·70) 0·57 (0·45–0·72)
Total plasma or serum 6 1220 40·7% 0·55 (0·47–0·64) 0·55 (0·44–0·69) 1·0% 0·47 (0·38–0·59) 0·47 (0·38–0·59)
Cholesterol esters 4 624 0% 0·58 (0·46–0·73) 0·58 (0·46–0·73) 0% 0·54 (0·41–0·73) 0·54 (0·41–0·73)
Adipose tissue 1 99 ·· 0·82 (0·49–1·35) 0·82 (0·49–1·35) .. 0·76 (0·38–1·53) 0·76 (0·38–1·53)
Overall 20 4347 53·9% 0·65 (0·60–0·72) 0·64 (0·56–0·74) 46·3% 0·57 (0·51–0·64) 0·57 (0·48–0·67)
Arachidonic acid
Phospholipids 14 2979 64·2% 0·99 (0·89–1·10) 1·01 (0·84–1·22) 54·6% 0·99 (0·86–1·14) 0·97 (0·78–1·22)
Total plasma or serum 6 1220 63·8% 0·73 (0·62–0·86) 0·74 (0·54–1·03) 66·5% 0·64 (0·52–0·79) 0·65 (0·43–0·99)
Cholesterol esters 4 624 12·3% 1·12 (0·90–1·40) 1·14 (0·90–1·46) 0% 1·22 (0·94–1·59) 1·22 (0·94–1·59)
Adipose tissue 1 99 ·· 1·56 (0·84–2·89) 1·56 (0·84–2·89) .. 1·67 (0·72–3·91) 1·67 (0·72–3·91)
Overall 20 4347 63·0% 0·96 (0·88–1·05) 1·01 (0·87–1·18) 61·2% 0·93 (0·83–1·04) 0·96 (0·79–1·17)
Data are relative risk (95% CI). *Effect estimates were pooled using inverse-variance weighted or random effects meta-analysis. †Multiple biomarkers were available in some studies, but only one biomarker per 
study was included for estimation of overall relative risks, therefore the overall number of studies and cases does not equal the sum of studies and cases per biomarker. ‡Fatty acids were modelled as continuous 
variables and relative risks were estimated per interquintile range (ie, the distance between the midpoints of the first and fifth quintiles).
Table 2: Pooled relative risks of type 2 diabetes according to levels of linoleic acid and arachidonic acid biomarkers*
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on the association between either linoleic acid or 
arachidonic acid biomarker levels and incident type 2 
diabetes (pinteraction≥0·47; appendix).
Compared with the main analyses, similar results were 
observed for linoleic acid and arachidonic acid biomarkers 
after exclusion of type 2 diabetes cases identified in the 
first 2 years of follow-up, and censoring of follow-up at 
6 years after baseline (appendix).
Discussion
In this consortium of 20 prospective studies across 
ten countries, biomarker levels of linoleic acid were 
inversely associated with incident type 2 diabetes, whereas 
levels of arachidonic acid biomarkers were not associated 
with type 2 diabetes. The magnitude of the association 
between linoleic acid biomarkers and type 2 diabetes was 
substantial, with high linoleic acid levels associated with a 
43% lower relative risk of type 2 diabetes across quintiles 
in the categorical analysis. To the best of our knowledge, 
this is the largest and most detailed biomarker assessment 
of omega-6 PUFA and type 2 diabetes, including across 
multiple lipid compartments. Despite the breadth and 
scope of the cohorts, associations did not seem to differ 
by age, BMI, sex, race, omega-3 PUFA levels, aspirin use, 
or variation in the genes encoding FADS.
Incorporation of linoleic acid into phospholipids alters 
membrane fluidity and might modulate insulin receptor 
activity.21 In a meta-analysis9 of 102 randomised controlled 
feeding trials, dietary PUFAs (predominantly linoleic 
acid) improved glycaemia, insulin resistance, and 
insulin secretion capacity, compared with carbohydrate, 
saturated fat, and for some endpoints even mono-
unsaturated fat. In other randomised controlled trials,22 
linoleic acid-rich vegetable oil reduced markers of inflam-
mation, visceral fat deposition, and hepatic steatosis. 
Because dietary linoleic acid intake correlates with levels 
of circulating and tissue linoleic acid,12 our biomarker-
based findings extend and expand these previous results 
by providing evidence that linoleic acid might have long-
term benefits for preventing the onset of type 2 diabetes, 
supporting clinical recommenda tions to increase dietary 
intake of linoleic acid-rich vegetable oils. Our novel 
findings also support the need for future studies to 
establish the potential influence and clinical effects of 
other influences (eg, pharmacological) on these fatty acid 
biomarkers, identify the downstream biological me-
diating pathways of these fatty acid biomarkers on risk of 
type 2 diabetes, and in vestigate potential novel influences 
Figure 1: Pooled relative risks of type 2 diabetes according to interquintile 
range* of linoleic acid biomarker, per lipid compartment
The association between linoleic acid and type 2 diabetes was assessed in 
multivariable models for each cohort, and the results were pooled using 
inverse-variance weighted fixed effects meta-analysis. If multiple biomarkers 
were available within a study, one was chosen for the overall analysis on the 
basis of its ability to reflect long-term dietary intake (in the following order of 
preference): adipose tissue, phospholipids, total plasma, and cholesterol esters. 
Similarly, data for erythrocyte phospholipids were preferred over plasma 
phospholipids if both were available from a cohort. References for all studies are 
shown in the appendix. RR=relative risk. AGES-Reykjavik=Age, 
Gene/Environment Susceptibility Study (Reykjavik). METSIM=Metabolic 
Syndrome in Men Study. MCCS=Melbourne Collaborative Cohort Study. 
FHS=Framingham Heart Study. 3C=Three City Study. EPIC-Norfolk=European 
Prospective Investigation into Cancer (Norfolk). EPIC-Potsdam=European 
Prospective Investigation into Cancer (Potsdam). ARIC=Atherosclerosis Risk in 
Communities. CHS=Cardiovascular Health Study. PIVUS=Prospective 
Investigation of the Vasculature in Uppsala Seniors. MESA=Multi-Ethnic Study of 
Atherosclerosis. HPFS=Health Professionals Follow-up Study. WHIMS=Women’s 
Health Initiative Memory Study. NHS=Nurses’ Health Study. KIHD=Kuopio 
Ischaemic Heart Disease Risk Factor Study. IRAS=Insulin Resistance 
Atherosclerosis Study. CCCC=Chin-Shan Community Cardiovascular Cohort 
Study. ULSAM-50=Uppsala Longitudinal Study of Adult Men-50. AOC=Alpha 
Omega Cohort. ULSAM-70=Uppsala Longitudinal Study of Adult Men-70. 
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(eg, pharma cological and lifestyle) on these downstream 
biological mediating pathways. Mendelian random-
isation studies23 should also assess the association 
between the common genetic variants that influence 
fatty acid concentrations and type 2 diabetes.
Despite the established benefits of PUFAs for blood 
cholesterol levels and glucose-insulin homoeostasis,9 
some scientists maintain that omega-6 PUFA is harmful 
for health.24 A main theorised harm relates to the 
conversion of linoleic acid to arachidonic acid, which has 
been considered as pro-inflammatory and potentially 
harmful for glucose metabolism, weight regulation, and 
eating behaviour.6 However, multiple studies indicate 
that variations in both dietary linoleic acid and 
arachidonic acid have little effect on circulating 
arachidonic acid levels, indicating close endogenous 
regulation of the metabolite.25 Additionally, arachidonic 
acid has important metabolites that actively resolve 
inflammation,26 and systematic reviews of trials have not 
identified pro-inflammatory effects of linoleic acid 
consumption.27 Indeed, a systematic review8 found that 
higher biomarker levels of arachidonic acid were 
associated with lower incidence of coronary heart disease. 
We found no evidence to suggest that arachidonic acid 
contributes to the development of type 2 diabetes. 
Together with the findings of previous experimental and 
interventional studies on metabolic risk factors, our 
findings do not suggest that high levels of dietary 
omega-6 PUFA are harmful. Additionally, although 
omega-3 and omega-6 PUFA has been hypothesised to 
compete, we did not identify any evidence of a 
physiologically relevant inter action in this large, well 
powered consortium analysis.
A 2016 nested case-cohort analysis from the European 
Prospective Investigation into Cancer (EPIC) cohort,28 
published during the preparation of our manuscript, 
found an inverse association between plasma phos-
pholipid linoleic acid and type 2 diabetes (HR per SD 
increase 0·80, 95% CI 0·77–0·83), and no significant 
association between arachidonic acid and type 2 diabetes 
(HR 1·02, 0·98–1·06). Our findings are consistent with 
this report, and include a worldwide perspective, using 
data from multiple lipid compartments and detailed 
assessment of potential effect modification, including by 
variation in the genes encoding FADS. Our study also 
Figure 2: Pooled relative risks of type 2 diabetes according to interquintile 
range* of arachidonic acid biomarker, per lipid compartment
Association between arachidonic acid and type 2 diabetes was assessed in 
multivariable models for each cohort, and the results were pooled using 
inverse-variance weighted fixed effects meta-analysis. If multiple biomarkers 
were available within a study, one was chosen for the overall analysis on the 
basis of its ability to reflect long-term dietary intake (in the following order of 
preference): adipose tissue, phospholipids, total plasma, and cholesterol esters. 
Similarly, data for erythrocyte phospholipids was preferred over plasma 
phospholipids if both were available from a cohort. References for all studies are 
shown in the appendix. RR=relative risk. HPFS=Health Professionals Follow-up 
Study. EPIC-Potsdam=European Prospective Investigation into Cancer 
(Potsdam). NHS=Nurses’ Health Study. WHIMS=Women’s Health Initiative 
Memory Study. FHS=Framingham Heart Study. EPIC-Norfolk=European 
Prospective Investigation into Cancer (Norfolk). MCCS=Melbourne 
Collaborative Cohort Study. 3C=Three City Study. PIVUS=Prospective 
Investigation of the Vasculature in Uppsala Seniors. MESA=Multi-Ethnic Study 
of Atherosclerosis. ARIC=Atherosclerosis Risk in Communities. 
CHS=Cardiovascular Health Study. AGES-Reykjavik=Age, Gene/Environment 
Susceptibility Study (Reykjavik). METSIM=Metabolic Syndrome in Men Study. 
IRAS=Insulin Resistance Atherosclerosis Study. KIHD=Kuopio Ischaemic Heart 
Disease Risk Factor Study. CCCC=Chin-Shan Community Cardiovascular Cohort 
Study. ULSAM-50=Uppsala Longitudinal Study of Adult Men-50. AOC=Alpha 
Omega Cohort. ULSAM-70=Uppsala Longitudinal Study of Adult Men-70. 
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appreciably reduces the possibility of chance findings or 
publication bias, compared with individual cohort reports, 
because we included most of the available cohorts with 
measured fatty acid biomarkers and assessment of 
incident type 2 diabetes. The inclusion of EPIC-InterAct 
in our pooled analysis would be unlikely to affect the 
conclusions of our study.
Little is known about how differences in fatty acid 
function between lipid compartments relate to health. Our 
analyses provided novel assessment of dose–response 
associations between omega-6 PUFA and type 2 diabetes 
in different lipid compartments. For linoleic acid 
biomarkers, all compartments (with the exception of 
adipose tissue, which was only assessed in one study) 
showed significant linear inverse associations with 
type 2 diabetes, suggesting a class effect of linoleic acid 
rather than primacy of any single compartment. In 
exploratory analyses, the protective association between 
linoleic acid and type 2 diabetes seemed to be linear 
in cholesterol esters and total plasma, but non-linear in 
phospholipids, where benefit appeared to plateau at very 
high levels. The biological and clinical relevance of this 
discrepancy warrants further investigation. Studies are 
also needed to define the dose–response relationship 
between a broad range of markers of linoleic acid 
intake and biomarker concentrations in different lipid 
compartments. For arachidonic acid biomarkers, there 
was little evidence for non-linearity for any of the lipid 
compartments. The opposing associations of erythrocyte 
phospholipids and plasma phospholipids with arachi-
donic acid identified by semiparametric analyses require 
further investigation; these results could be due to 
chance because arachidonic acid concentrations in these 
two compartments are highly correlated and are known 
to readily interexchange.29 Consistent with this sugges-
tion, in the EPIC cohort,28 levels of plasma phos pholipid 
arachidonic acid were not associated with type 2 diabetes. 
Our new findings of a protective asso ciation between 
arachidonic acid in total plasma and incident type 2 
diabetes, based on findings in six cohorts, should be 
explored further.
Our investigation has important strengths. We included 
prospective cohorts, which minimised the likelihood of 
selection bias. Our use of biomarkers avoided recall bias 
associated with self-reported intake and allowed objective 
assessment of linoleic acid and arachidonic acid levels. 
Collaboration between 20 cohorts enabled simultaneous 
investigation of multiple lipid compartments, which 
could be cost prohibitive in a single study. Harmonised, 
predefined analysis protocols standardised exposures, 
outcomes, covariates, and statistical modelling, reducing 
post-hoc-driven reporting and heterogeneity across 
studies. The prespecified analytic plan and inclusion of 
20 (77%) of the 26 identified global cohorts greatly 
reduced publication bias. The large numbers of partici-
pants and events increased statistical power to explore 
effect modification. Results were consistent in sensitivity 
analyses, increasing confidence in the robustness of 
findings and underlying model assump tions. Inclusion 
of multiple cohorts and nations with diverse demo-
graphic, lifestyle, and dietary characteristics enhanced 
generalisability.
Our study also has limitations. Few data were available 
on adipose tissue, reducing power and precision to assess 
its relevance for type 2 diabetes. Although multiple races 
and ethnicities were included, most participants were of 
European descent and statistical power was low with 
respect to differences in other ethnic groups, although 
central risk estimates for linoleic acid biomarkers were 
protective in each group. Fatty acid biomarker levels were 
assessed at baseline, and changes over time would 
attenuate findings toward the null hypothesis, causing 
underestimation of magnitudes of true associations. 
Linoleic acid biomarkers reflect dietary intake and other 
factors such as metabolism, so differences in type 2 
diabetes risk should not be interpreted as entirely 
attributable to dietary linoleic acid. We did not assess 
other fatty acid biomarkers, which should be the subject 
of future investigations—particularly saturated fatty acids 
such as palmitic acid, which has shown pro-diabetogenic 
effects in experimental studies.30–32 In addition, the re-
liability of type 2 diabetes ascertainment was likely to 
have differed across the cohorts, which might have caused 
some outcome misclassification and underestimation 
of true associ ations. Our findings are relevant for the 
incidence of type 2 diabetes, but not type 1 diabetes. 
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Figure 3: Pooled relative risks of type 2 diabetes per quintile of linoleic acid 
and arachidonic acid biomarker
Association of linoleic acid and arachidonic acid levels with type 2 diabetes was 
assessed in multivariable models for each cohort, and results were pooled using 
inverse-variance weighted meta-analysis. The lowest quintile was used as the 
reference group. For studies in which multiple biomarkers were available, 
one was chosen for the overall analysis on the basis of its ability to reflect 
long-term dietary intake (in the following order of preference): adipose tissue, 
phospholipids, total plasma, and cholesterol esters. Similarly, data for 
erythrocyte phospholipids was preferable to plasma phospholipids if data on 
both biomarkers were available. The Age, Gene/Environment Susceptibility Study 
(Reykjavik) was excluded from these analyses due to the small number of patients 
who developed incident type 2 diabetes, so the effect estimates were pooled 
from the other 19 cohorts. RR=relative risk. Q=quintile. 
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measured covariates, including by other fatty acid 
biomarkers, cannot be fully excluded. However, the mag-
nitude of the observed association between linoleic acid 
biomarkers and the incidence of type 2 diabetes, 
consistency across biomarker compartments, inclusion 
of varied popula tions with diverse underlying charac-
teristics, and sup portive biological plausibility from inter-
ventional trials of risk factors suggest that our findings 
are not solely due to statistical chance and uncontrolled 
confounding.
In conclusion, this international collaboration of 
20 prospective cohorts showed that biomarker levels of 
linoleic acid, the major dietary omega-6 PUFA, were 
inversely associated with the risk of incident type 2 
diabetes, whereas levels of arachidonic acid were not 
significantly associated with risk of the disease.
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